08:44 AM EDT, 10/03/2025 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Friday that it has agreed to settle a patent lawsuit against Dr. Reddy's Laboratories (RDY) related to its cholesterol drugs Nexletol and Nexlizet.

Under the terms of the settlement, Dr. Reddy's Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the US before April 19, 2040, Esperion said.

Esperion said it sued Dr. Reddy's in response to an abbreviated new drug application that Dr. Reddy's filed to market a generic version of the drugs before the expiration of the related patents.

The company also said patent lawsuits are ongoing against Alkem Laboratories, Aurobindo Pharma and an affiliate, MSN Pharmaceuticals and an affiliate, Renata and an affiliate, and Sandoz.

Shares of Esperion Therapeutics ( ESPR ) were up 3.8% in recent premarket activity Friday, while Dr. Reddy's were slightly higher.